BIOTRONIK is releasing in the United States its Acticor line of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). These include the Acticor DX and CRT-DX, both of which can take advantage of the company’s Plexa ProMRI S DX lead.
A single Plexa ProMRI S DX lead is capable of providing dual-chamber diagnostic information, something that otherwise would have required an additional lead.
The devices all work with BIOTRONIK’s new DF4 header configuration that relies on a penta-polar cable design that makes implantation easier and faster. Overall shape of the implants is smaller and they’re smoother to the touch, leading to a more comfortable outcome.
The DX in the name of the implants refers to the ability of the devices to detect silent atrial fibrillation, which is a common cause of strokes, and discriminate for supraventricular tachycardia, in the process reducing unnecessary shocks.
BIOTRONIK believes that not only will these devices improve clinical outcomes, but that cost savings will also be realized due to shorter procedures, fewer complications, and fewer cardiac problems that these implants are designed to overcome.
“Acticor DX device systems offer unmatched insight into the atrium without the risk or costs associated with an unnecessary atrial lead,” said Ryan Walters, President of BIOTRONIK, in a published statement. “Clinical evidence suggests this additional atrial data dramatically improves the accuracy of rhythm classification, directly informing real-time therapy for patients.1 DX technology, combined with Acticor’s new continuous automation capability, facilitates a more comprehensive understanding of each patient’s disease state. This enables customized treatment with streamlined workflows that translate into cost savings for health systems and improved outcomes for patients.”